Daiichi Sankyo Company, Limited

Kinki University

Amgen Inc.

Daiichi Sankyo Europe Gmbh

Kimio Yonesaka

Kazuhiko Nakagawa

Daniel Freeman

Sabine Blum

Matthias Schneider

Xiaoping Jin

Robert Allen Beckman

Renee Jeanne Mendell-Harary

Kenji Hirotani

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low. The invention is also directed to methods of performing an ELISA, including sequential steps of contacting a solid surface with a plurality of solutions each comprising in turn a capture antibody, a blocking agent, a sample suspected of containing an analyte, a detection antibody and an enzyme conjugate, in which the solid surface is subjected to a wash process after each sequential step.

Protein biomarker and uses thereof

A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.

Method for selecting individuals to be administered immune checkpoint inhibitor

Growing community of inventors

Osakasayama, Japan

Kimio Yonesaka